News AZ sells migraine drug rights to Grunenthal for $300m AZ says migraine outside its strategic focus.
News Five UK pharma companies "named and shamed" by watchdog Companies' actions discredited the industry, says PMCPA.
News EU regulator begins publishing detailed study data European Medicines Agency proactively publishes clinical study reports for first time.
News AZ sells US, EU and Latin America rights to gout drug AZ focused on sales target set by CEO Pascal Soriot.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.